Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus R-CHOP for primary mediastinal large B-cell lymphoma
ChiCTR2100044313Phase 2Recruiting
- Sponsor
- Affiliated Cancer Hospital of Xinjiang Medical University
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in primary mediastinal large B-cell lymphoma (PMBCL), sponsored by Affiliated Cancer Hospital of Xinjiang Medical University. Primary endpoint: Objective remission rate. Started Jun 2021; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on ChiCTR2100044313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044313.